CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 79.75% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

Acumen Pharmaceuticals posts smaller than expected Q3 loss

By Reuters News


Overview

  • Biopharmaceutical company posted narrower-than-expected Q3 loss from operations and net loss

  • R&D expenses declined yr/yr, while general and administrative expenses rose slightly

  • Cash balance expected to support operations into early 2027


Outlook

  • Company expects topline results from ALTITUDE-AD Phase 2 study in November 2026

  • Company targets IND filing for EBD program lead candidate in mid-2027


Result Drivers

  • LOWER TRIAL COSTS - Co said decreased R&D expenses were mainly due to reduced manufacturing, materials, and CRO costs for ALTITUDE-AD trial

  • EBD PROGRAM SPENDING - Co said increased spending for EBD program partially offset lower ALTITUDE-AD trial costs


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Net Loss

Beat

$25.37 mln

$30.32 mln (5 Analysts)

Q3 Income From Operations

Beat

-$25.81 mln

-$30.68 mln (5 Analysts)

Q3 Loss Per Basic Share

$0.35

Q3 Operating Expenses

$25.81 mln


Analyst Coverage

  • The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 6 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the biotechnology & medical research peer group is "buy."

  • Wall Street's median 12-month price target for Acumen Pharmaceuticals Inc is $8.00, about 304% above its October 23 closing price of $1.98


Reuters Recommended Reads

  • Oct 24 - Amgen drug combined with immunotherapy extends survival in lung cancer trial

  • Oct 23 - Revolution's Rasonque improves survival across subgroups in pancreatic cancer patients

  • Oct 23 - Bristol Myers discloses patient death in early-stage cell therapy study


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.